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Summary: The assay of myelin basic protein in body fluids has potential clinical importance as a routine indicator
of demyelination.
Preliminary details of a competitive enzyme immunoassay for this protein have previously been published by the
author (Groome, N. P. (1980) J. Neurochem. 35, 1409-1417).
The present paper now describes the adaptation of this assay for use on human plasma and various aspects of routine
data processing.
A commercially available cuvette system was found to have advantages over microtitre plates but required a permuted
arrangement of sample replicates for consistent results. For dose interpolation, the standard curve could be fitted to
a three parameter non-linear equation by regression analysis or linearised by the logit/log transformation.
Bestimmung des basischen Myelinproteins mit Gilford Enzymimmunassay-Küvetten
Zusammenfassung: Die Bestimmung des basischen Myelinproteins in Körperflüssigkeiten hat möglicherweise klinische
Bedeutung in der Diagnostik von Demyelinisierungsprozessen.
Eine Methode zur Messung durch „competitive enzyme immunoassay" ist für dieses Protein vom Verfasser beschrie-
ben worden (Groome, N. P. (1980) J. Neurochem. 35, 1409-1417).
In der vorliegenden Arbeit wird die Anpassung dieser Bestimmungsmethode für menschliches Blutplasma beschrieben
und eine Routineauswertung der Meßdaten vorgestellt. Ein kommerziell erhältliches Küvettensystem ist vorteilhafter
als "microtitre plates", bedarf aber einer permutierten Anordnung der identischen Proben, um zuverlässige Ergebnisse
zu liefern. Die Standardkurve entspricht einer nicht-linearen Gleichung mit 3 Parametern, die mittels Regressions-
analyse erstellt wurde oder durch logit/log Transformation linearisiert werden kann.
Introduction titre plates, the current batches of these cuvettes show
a phenomenon termed the 'smile effect' i.e. the end
Myelin basic protein is nervous system specific and the
 wdb Qn each $trip giye highef readings than those ta the
major protein component of myelin (1). As such it is an
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ideal substance to assay in body fluids as a measure of "j «.
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pa len s ^ ,, ). would allow any laboratory to do routine myelin basic
We have recently described the principle of an Enzyme
 protein assays.
Linked Immunoassay procedure1) for myelin basic
protein which offers certain advantages over radio-
immunoassay as a routine tool (4). We show here that
 Materials md Methods
the assay can be applied to plasma and describe some
useful data processing procedures. Gilford immunoassay cuvettes (lot number 1 02592) were ob-r
 tained from Gilford Instruments Inc., Ohio. Logit-log graph
We also report our experience with Gilford immunoassay
 paper was obtained from Heffers Bookshop, Cambridge, U.K.
cuvettes as a solid phase. Although preferable to micro-
 The EUSA for myelin basic protein was carried out essentially
as described previously (4) for use in microtitre plates. It was
necessary with the Gilford cuvettes to use 0.25 ml volumes of
: ELISA - Enzyme LinKed „«adsorbent £, ^ ^^^^^' ** * """
Assay.
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Coating of wells with antigen
A solution of bovine myeiin basic protein at 0.3 mg/1 in 0.1 mol/1
phosphate buffer pH 6.0 was prepared in a siliconised beaker.
Bovine myeiin basic protein is used instead of human myeiin
basic protein for coating since it is easier to obtain in a highly
purified state. 0.25 ml was placed in each cuvette and the cuvette
strips stood overnight at 25 °C in a moist atmosphere. The
cuvette strips were then washed 10 ÷ with wash solution (12 g/1
sodium chloride, 0.5 g/1 Tween 80), leaving them for 2 h in the
last wash to allow loosely bound myeiin basic protein to detach
(5).
They were then given a distilled water rinse and allowed to air
dry. Cuvette strips were then stored over silica gel until required.
Preparation of plasma samples for assay
Fresh citrated blood samples were centrifuged to obtain plasma.
These were either analysed immediately or stored at - 20 °C (6).
Each plasma sample was mixed with one volume of 0.2 mol/1
citrate buffer pH 3.7 and a further volume of 0.05 mol/1 phos-
phate buffer pH 7.0 containing 12 g/1 sodium chloride, 0.5 g/1
Tween 80 and 0.25 g/1 calf thymus histones. The solution was
then heated at 100 °C for 5 minutes, during which time the bulk
of the plasma protein precipitates. Myelin basic protein is left
quantitatively in solution (6). After centrifugation the super-
natant was used for ELISA.
Procedure
ELISA Stage 1
A control sample was prepared by mixing equal volumes of the
supernatant from pooled normal human plasma with a 1:160000
dilution of a rabbit anti-human myeiin basic protein serum
(kk42). Antiserum dilution was made in 0.2 mol/1 disodium
hydrogen phosphate containing 12 g/1 sodium chloride, 0.5 g/1
Tween 80 and 0.5 g/1 calf thymus histones. This serum reacts
well with human and bovine myeiin basic protein. Histones are
always added to the buffers immediately before use to prevent
the development of inhibitory activity (6).
The standard curve was prepared by adding known amounts of
human myeiin basic protein (courtesy ofM. Kies) to pooled
normal human plasma. Samples were citrated and boiled and
mixed with antiserum as for the control. A blank was prepared
by mixing an equal volume of the supernatant from treated
normal plasma with buffer alone. The solutions were allowed to
stand at room temperature for 4 h before the next stage.
ELISA Stage 2 (as finally adopted)
Twenty 0.4 ml aliquots of the control mixture were placed in a
permuted distribution in ten cuvette strips occupying the posi-
tion labelled A and B as in table 2. Ten aliquots of each of the
standards occuped positions C, D, E, F, G, H and I and ten ali-
quots of blank occupied J. The reasons for adopting this per-
muted distribution are described in a later section. The cuvette
strips were then placed in a moist box overnight at room temper-
ature on a device providing slight agitation.
ELISA Stage 3
The cuvette strips were emptied by shaking and then washed
10 X with wash solution. To remove the last traces of liquid they
were struck firmly several times onto paper towelling. 0.25 ml of
goat anti rabbit-IgG/peroxidase conjugate at a dilution of
1:5000 in conjugate dilution buffer (4) was then added. This
was allowed to react for 6 h at room temperature with the
cuvettes in a moist box, again with slight agitation.
ELISA Stage 4
The cuvette strips were washed and emptied as before. Then
0.25 ml of peroxidase substrate (4) was added and incubation
carried out overnight at room temperature with agitation. The
experiments reported here all used 0.1 mol/1 phosphate buffer
pH 7.0 as reaction buffer (4). Recently we have found that faster
rates of reaction can be achieved in 0.1 mol/1 citrate buffer
pH 4.0, other conditions remaining the same.
E LISA Stage 5
The optical faces of the cuvette strips were wiped with tissue and
the absorbance at 420 nm at all positions measured with a Gil-
ford cuvette reader referenced to air.
ELISA Stage 6'
The ten absorbance values for each cuvette strip at a time were
typed into a computer, which then carries out the following
routine calculations:
1. Calculates the average of the A's, B's, C's etc. from the
permuted distribution.
2. Subtracts the blank.
3. Averages A and B and designates this the 100% level, in the
absence of a competitor.
4. Expresses the average of C, D, E etc. as a % of the control.
Dose interpolation
Linearisation of the standard* curve could be obtained by plotting
(% of the control) versus myeiin basic protein concentration on
Logit log graph paper. Alternatively the data were fitted by
computer to a three parameter non-linear equation by regression
analysis (7). The latter method was used routinely.
Procedure for unknown samples
Plasma samples containing unknown amounts of myeiin basic
protein were citrated and boiled as for the standard curve. For
each eight samples to be analysed ten strips are required in addi-
tion to those for the standard curve. Positions A arid B are again
used for controls but now all eight remaining positions (C-J) are
used for unknowns. The (% of the control) for each unknown is
calculated and the corresponding myeiin basic protein concentra-
tion calculated from the previously determined regression equa-
tion.
Results
A3 competitive ELISA
The A 3 competitive assay principle (8) has not been
widely used. A similar assay to that described here has,
however, been applied to factor VIII related antigen (9),
although this was of much lower sensitivity. The assay
principle is shown in figure 1. Full details of the initial
development of the assay for myeiin basic protein have
been described elsewhere (4).
Adaptation of the ELISA method to use Gilford cuvettes
This required few changes from the method using micro-
titration plates (4). A minimum volume of 0.25 ml was
used to avoid meniscus effects and to cover the optical
path for the final absorbance measurement. Figure 2
shows some of the results of an myeiin basic protein assay
in which all ten positions oil a separate strip were used
to replicate each dose level. The replicates within one
strip did not give values randomly distributed about a
mean but a characteristic pattern of reactivity with a
central trough. Quality control procedures on Gilford
cuvettes are claimed to be rigorous and do predict this
phenomenon termed the 'smile' effect (w). The magnl·
tude of the smile effect may well vary according to the
nature of the absorbed material and the principle of the
particular immunoassay. It should be noted that Gilford
cuvettes are designed for use in an automated processor
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Competitive, heterogenous method for detection of antigen
Step 1 eag I7=a Well is coated with known amount
of antigen.
Step 2
StepS
Step 4
Sample antigen and specific anti-
body are added. Bound and free
antigen compete for antibody.
Bound and free complexes are
separated by washing.
Enzyme-labelled antiglobulin is
added and binds to antibody. Free
conjugate is removed by washing.
Chromogenic substrate is added.
The optical density is reduced in
proportion to the amount of
competing antigen.
A standard curve is prepared of a range of competing antigen
concentrations. The concentration of an unknown sample antigen
is determined from the standard curve.
= antigen
= specific antibody
= 2nd antibody
E
á
Ñ
= enzyme
= substrate
= coloured substrate after
enzyme-catalysed
reaction
Fig. 1. The principle of the A3 Competitive Immunoadsorbent
Assay.
(PR50) so that random errors due to variations in the
washing treatments and reagent additions will be some-
what greater in the present study than if the whole
assay was automated. Nevertheless, many workers will
require to use these cuvettes as they are here and will
presumably find these results more typical.
Further characterisation of the smile effect
To define more precisely the reactivity of the different
cuvette positions in this assay the following experiment
was done. Fifteen strips were coated identically with
myelin basic protein and were then reacted with anti
myelin basic protein serum, exactly as in the control
for figure 2. The assay was then completed. The results
suggested that the smile was slightly lop-sided (fig. 3,
tab. 1).
Furthermore, considerable variation occurred in corre-
sponding well positions from strip to strip. The end
positions were more variable than the others. This varia-
tion could have two components (1) random error (2)
systematic error due to variations in the mean from
strip to strip. The latter could have two causes. Either
variation in experimental strip handling or manufacturing
differences. The data of table 1 supported the idea that
systematic variation was the major cause, of between-
strip variability since it can be seen that some strips gave
high values at all positions (e.g. marked o), whilst others
gave low values at all positions (e.g. marked o).
Attempts to minimise strip to strip variation
Since the initial experiments shown in figure 3 and table 1
were done efforts have been made to make the washing
procedures more reproducible. Although these slightly
reduced the systematic variation from strip to strip they
did not eliminate it. Thus, consideration was given as to
the best method of using these cuvette strips to allow
the most reliable comparisons between samples.
~ 2 3 4 ~ 5 6 7
Guvette position number
Fig. 2. Myelin basic protein immunoassay in <—
All the replicates at each dose level were placed <
cuvette strip. Values within a strip were not ™*0™
distributed about a mean but had a characteristic distnbu
tion, termed the *smile' effect.
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_L
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Cuvette position number
Fig. 3. Further characterisation of the 'smile' effect. Fifteen
cuvette strips were used entirely for control samples in a
myelin basic protein assay.
Between strip mean (n = 15) for each cuvette position.
Bars show ± 1 standard deviation.
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Tab. 1. Actual data (absorbance at 420 nm) for ten of the cuvette strips used for Fig. 3.
• = strips giving high values at all positions ï = strips giving lower values
The data also show the permutation system used to derive a mean in a way which cancels out the smile effect.
Cuvette position number
1 2 3 10
Strip 1
Strip 2
Strip 3
Strip 4
Strips
Strip 6
Strip 7
Strip 8
Strip 9
Strip 10
Mean
Sample l.A
Sample 6.F
A
1.135
J
1.008
I
1.303
Ç
0.907
G
1.273
F
1.438
E
1.250
D
1.495
C
1.340
B
1.320
= 0.958
= 0.958
B
1.045
A
0.896
J
1.150
I
0.916
H
1.020
G
1.298
F
0.981
E
1.170
D
0.978
C
1.190
Sample 2.B =
Sample 7.G =
C
1.040
B
0.985
A
1.080
J
0.780
I
0.790
H
1.098
G
0.950
F
1.001
E
1.005
D
1.080
0.981
1.031
D
0.998
C
0.702
B
0.927
A
0.895
J
0.787
I
1.068
H
0.978
G
1.150
F
0.833
E
1.150
E
0.89
D
0.809
C
0.834
B
0.698
A
0.665
J
0.956
I
0.802
H
1.070
G
0.817
F
0.936
Sample 3.C =
Sample 8.H =
F
0.969
E
0.860
D
0.876
C
0.892
B
0.700
A
0.990
J
0.907
I
1.010
H
0.802
G
1.020
1.002
0.983
G
1.004
F
0.949
E
1.138
D
0.830
C
0.716
B
1.018
A
0;950
J
1.130
I
0.828
H
1.070
H
1.096
G
1.070
F
0.908
E
0.888
D
0.815
C
1.048
B
0.950
A
0.980
J
1.020
I
1.170
I
L 120
H
0.860
G
1.038
F
0.720
E
0.770
D
1.110
C
0.910
B
1.220
A
0.990
J
1.240
Sample 4.D = 0.976
Sample 9.1 =0.986
J ·
1.000
I
0.857
H
0.928
G o
0.690
F o
¼.849
E
1.058
D
0.770
C
1.350
B
0.950
A ·
1.000
Sample 5.E =1.018
Sample 10.J = 0.998
Coefficient of variation for A-J = 2.4%
A procedure for using the Gilford cuvettes for precise
sample comparisons
Before the myelin basic protein assay could be used with
confidence for the routine analysis of clinical samples
several questions needed to be considered. Firstly, what
level of confidence was required in the percentages of the
control value determined at each dose level? Secondly,
how many replicates were required to achieve this degree
of confidence? Thirdly, how were the replicates at each
dose level to be distributed? It was decided that the
precision would be adequate if an absorbance 7% below
the control level was significant at the 95% confidence
level. The distribution of sample replicates was critically
important for this standard to be met. If the replicates
(e.g. N = 5) at each dose level were all arranged on a
single strip the smile effect would cause the two halves
of the strip to differ to start with. If the whole strip was
used for ten replicates, although the smile effect was
overcome, the assay then became unduly sensitive to
systematic differences between strips caused by handling
or manufacturing differences. It was not justifiable to
assume that the standard deviation of
SD (within strip)
strip means =- — -  . The SD (within strip)
is largely caused by the smile effect and does not allow
one to assess the magnitude of between strip variation.
Another possible arrangement would place all the repli-
cates of one sample in well position 1 on a series of
strips, and the other samples in positions 2, 2,2, 3,3,3,
etc. This arrangement would also allow the distortion
of the assay results by the smile effect.
A logical solution to the problem posed above would be
to permute the sample replicates as shown in table 2.
Early results soon confirmed that samples could be very
precisely and unambiguously compared by this method.
The standard deviation of permuted sample means with-
in a ten strip array has a standard deviation of about
2.5% (tab. 1). The following procedure has now been
adopted routinely for the analysis of unknown. Ten
strips are used for two controls (set A and set B) seven
standards (C-I) and one blank (J). Each successive ten
strips also contain two controls but now have unknown
samples at all the remaining positions. A simple computer
programme analyses the data in the following way:
1) Absorbance values are requested strip by strip for
each batch often strips.
2) The mean of the permuted replicates for A, B, C, etc.
is calculated.
3) The blank is subtracted.
4) A and B are averaged to give the control value and
all the standards are calculated as a percentage of the
control.
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Tab. 2.
wth the s .it help
«vuitog . permuted distribution of sample replicates. A and B are controls, C-I standards and
n « ? * absorbance values at 420 nm and subsequent data processing which is done routinely
simple computer programme. Details as described in "Methods".
Cuvette position number
1 2 3 10
Strip 1
Strip 2
Strip 3
Strip 4
Strip 5
Strip 6
Strip 7
Strip 8
Strip 9
Strip 10
Mean
Sample l.A =
Sample 6.F =
A
0.961
J
0.179
I
0.391
H
0.386
G
0.659
F
0.580
E
0.869
D
0.606
C
1.002
B
0.755
0.933
0.551
B
0.796
A
1.283
J ..
0.278
I
0.290
H
0.358
G
0.386
F
0.606
E
0.543
D
1.332
C
0.613
Sample 2.B =
Sample 7.G =
C
0.691
B
1.165
A
1.015
J
0.192
I
0.298
H
0.317
G
0.463
F
0.441
E
1.187
D
0.683
0.919
0.438
D
0.638
C
1.247
B
1.001
A
0.868
J
0.186
I
0.284
H
0.361
G
0.325
F
0.747
E
0.570
Sample
Sample
E
0.509
D
0.814
C
0.798
B
0.728
A
0.846
J
0.183
I
0.283
H
0.274
G
0.542
F '
0.415
3.C = 0.854
8.H = 0.349
F
0.409
E
0.774
D
0.795
C
0.756
B
0.803
A
0.735
J
0.185
I
0.251
H
0.433
G
0.361
G
0.354
F
0.596
E
0.586
D
0.757
C
0.920
B
0.821
A
0.683
J
0.171
I
0.378
H
0.327
H
0.290
G
0.517
F
0.649
E
0.649
D
0.747
C
0.753
B
1.040
A
0.870
J
0.221
I
0.301
Sample 4.D = 0.803
Sample 9.1 =0.313
j
0.269
H
0.398
G
0.436
F
0.492
E
0.643
D
0.637
C
1.060
B
0.823
A
1.352
J
0.187
Sample 5. E '=
Sample 10.J =
j
0.197
.
0.381
H
0.342
G
0.333
F
0.571
E
0.585
D
1.023
C
0.698
B
1.255
A
0.717
0.691
0.198
- blank Myelin basic protein
Oig/0
A 0.735
B 0.721
C 0.656
D 0.605
E 0.493
F 0.353
G 0.240
H 0.151
I 0.115
J. 0.000
control = 0.728 100
90.2
83.2
67.8
48.4
32.9
20.7
15.7
1.95
3.91
7.81
15.62
31.25
62.50
125.00
The practice of having controls on the plate with each
batch of standards and unknowns gives the assay a high
degree of robustness and thus enhances the confidence
which can be placed in unknown values. This is partic-
ularly important when large numbers of samples are
being analysed.
Assay of myelin basic protein in plasma
Table 2 shows the data obtained from an experiment
which used ten cuvette strips to generate a standard
curve for the myelin basic protein assay. Table 1 shows
the data obtained on another occasion when all ten
sample positions were used for controls. The coefficient
of variation (CV) of the mean values within the typical
ten strip array of table 1 was 2.4%. The CV of the mean
of the two controls on a batch of 10 plates would there-
fore
2
·
4
The parameter which was to be calculated for each
sample i.e.
mean value for sample
Snean value for controls
J. din. Ghem. Clin. Biochem. / Vol. 19,1981 / No. 10
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is the ratio of two values each with different error. The
CV of the ratio can be calculated from statistical theory
as
2,4 2 L6y)2 =
'
 JOO
Thus any sample which in a given 10 X 10 array gave a
value less than 94% of the mean of the controls would
be significantly different from the control (p =? 0.05).
The detection limit of the assay shown in figure 4 and
table 2 is therefore around 1.5 ìg/l of plasma.
Estimation of error in unknown values
Since the response parameter (% of control) has a CV of
approx. 3% its valu'e for each unknown will have 95%
confidence limits 6% above and 6% below the actual
Value. The estimated maximum (p - 0.05) minimum
(p = 0.05) and mean myelin basic protein concentration
were then determined, for each unknown, from the
standard curve. Because of the shape of the dose
response relationship the upper and lower confidence
limits on unknown myelin basic protein concentrations
were not symmetrical about the mean.
100
e so
§
B 60
ató>
i 40
I I I I I I I I
0 10 20 30 40 50 60
Myelin basic protein l/ig/U
Fig. 4. Standard curve for plasma myelin basic protein assay.
•—· actual experimental points.
ï computer fitted points after curve fitting to Equa-
tion 1 by non linear regression analysis.
Regression constants:
a = 5.35 b=1296 c = 12.28
The figure above each point indicates the percentage
difference between actual and predicted values at each
dose level.
100-
ïï
ï 20
2 5 .10 20 50
Myelin basic protein l/ig/l]
100
Fig. 5. Logit-log plot of myelin basic protein ELISA data.
Dose interpolation
Figure 4 shows a direct plot of (% of control) versus
myelin basic protein concentration from the data of
table 2. Figure 5 shows the same data plotted on Logit-
log graph paper. Good linearisation was found from
2-60 ìg/l myelin basic protein. Figure 4 also shows
computer fitted points for the same data. The equation
fitted is:
(ax + b)
x + c Eq. 1
where
y = percentage of control
÷ = concentration of myelin basic protein 0*g/l)
a, b, c = constants fitted by the computer
The percentage differences between each experimental
point and the fitted curve are shown on the graph. The
myelin basic protein concentrations in unknown samples
were now readily determined from equation 1.
Discussion
Enzyme linked immunoadsorbent assays based on anti-
gen adsorption to polystyrene can be used for antigen
and antibody assay using a variety of different principles
(8). However, any worker who has tried quantitative
ELISA's using microtitre plates will be familiar with the
frustrating problems of achieving long term consistency
of results.
It has been shown that wells near the edges of the plates
often give abnormally high readings and that there is
often a non random distribution of readings within the
plate (10,11). Between batch variability can be con-
siderable as the manufacturers quality control procedures
rarely include tests of protein binding (11). Selection of
an acceptable batch of microtitre plates (10) is com-
plicated by the fact that manufacturers may occasionally
pool batches for distribution.
Given such published information and the verbal wisdom
of those who have learned first hand it will be surprising
if microtitre plates retain their advocates for quantitative
ELISA. Several manufacturers of these plates have
J. Clin. Chem. Clin.-Biochem. / Vol. 19,1981 / No. 10
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attempted to divert attention from these shortcomings
by developing sophisticated plate washers and through
the plate reading photometers. These do not compensate
for the above defects which stem from the difficulty of
moulding large polystyrene structures reproducibly.
Gilford Instruments have recently developed a poly-
styrene cuvette system which serves first as a solid phase
adsorbent and later as an optical cuvette for absorbance
measurements. A simple manual reader for these cuvettes
and a fully automated sample processor (PR50) for all
the stages of ELISA are also available. A high standard
of quality control is claimed for the cuvettes and each
batch is tested for its protein binding characteristics.
We have found these cuvettes convenient to use. However,
the 'smile* effect phenomenon described here does
detract from the simplicity of their usage. It means that
a permuted distribution of ten sample replicates is the
only logical arrangement. However, since in microtitre
plates there is no logical way to arrange replicates the
Gilford cuvettes are, in our view, a significant improve-
ment.
The 'smile' effect is believed to be due to temperature
gradients which arise in each curvette strip during
moulding. It is probable that its magnitude will be
significantly reduced in future batches of the cuvettes.
Some assay types seem to give a more marked 'smile'
than others (Groome, unpublished).
The ELISA for plasma myelin basic protein works well
and has several advantages over radioimmunoassay as a
possible routine tool in neuropathology (4). The acid
extraction procedure ofDelassalle et al. (6) is valuable
and removes many irrelevant plasma components. These
can sometimes interfere with ELISA's on low dilution
of serum or plasma (12).
Workers interested in the future developments in ELISA
methodology should note that it is also possible to
adsorb antigens to polystyrene spheres or couple them
covalently to nylon (13).
ELISA's based on such solid phase supports may over-
come the disadvantages of the currently available
moulded polystyrene formats in providing a randomly
distributed binding capacity.
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